Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 32.4% in March

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant drop in short interest during the month of March. As of March 31st, there was short interest totaling 890,908 shares, a drop of 32.4% from the March 15th total of 1,318,064 shares. Based on an average daily volume of 3,378,307 shares, the short-interest ratio is presently 0.3 days. Currently, 5.1% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biorestorative Therapies presently has an average rating of “Sell”.

Biorestorative Therapies Trading Up 2.8%

Shares of NASDAQ BRTX traded up $0.01 during midday trading on Wednesday, reaching $0.25. The company’s stock had a trading volume of 890,443 shares, compared to its average volume of 8,282,655. Biorestorative Therapies has a fifty-two week low of $0.19 and a fifty-two week high of $2.05. The stock has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.95. The stock has a market capitalization of $6.45 million, a price-to-earnings ratio of -0.16 and a beta of 0.37.

Biorestorative Therapies (NASDAQ:BRTX) last released its earnings results on Thursday, March 26th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). Biorestorative Therapies had a negative net margin of 3,956.11% and a negative return on equity of 430.91%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.15 million. As a group, equities analysts anticipate that Biorestorative Therapies will post -1.43 EPS for the current year.

Hedge Funds Weigh In On Biorestorative Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. DRW Securities LLC bought a new position in shares of Biorestorative Therapies in the fourth quarter valued at $55,000. Citadel Advisors LLC bought a new position in shares of Biorestorative Therapies in the third quarter valued at $152,000. Finally, Virtu Financial LLC grew its stake in shares of Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares in the last quarter. 69.38% of the stock is owned by institutional investors.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.